Matthew Lunning, DO, FACP, presents the case of a man with diffuse large B-cell lymphoma and reviews the available treatment options, including options after relapse and chemorefractory disease.
EP. 1: Case Presentation: A 64-Year-Old Man with Diffuse Large B-Cell Lymphoma
Matthew Lunning, DO, FACP, presents the case of a 64-year-old man with diffuse large B-cell lymphoma (DLBCL) and shares his initial impressions.
EP. 2: Chemorefractory Disease in Second-Line DLBCL Treatment
An expert explains the options for patients with DLBCL who develop chemorefractory disease in second-line treatment.
EP. 3: Available Third- and Further-Line Treatment Options for Transplant-Ineligible R/R DLBCL
Dr Matthew Lunning describes the available third- and subsequent-line treatments for patients with relapsed/refractory DLBCL (R/R DLBCL) who aren’t eligible for transplant.
EP. 4: R/R DLBCL: Safety and Efficacy Data from the L-MIND Trial
A review of the methods and data from a clinical trial investigating a combination therapy for relapsed/refractory DLBCL.
EP. 5: R/R DLBCL: Data from the RE-MIND2 Trial
Matthew Lunning, DO, FACP, shares data from the RE-MIND2 trial and explains how it compares to the L-MIND trial.
EP. 6: Unmet Needs and Future Directions for Patients with R/R DLBCL
Dr Matthew Lunning closes his discussion on DLBCL by highlighting unmet needs in the treatment landscape.
2 Commerce Drive Cranbury, NJ 08512